A rare case of early onset intrahepatic cholestasis of pregnancy

Saraswathi H. L.*, Trishula Gurunath Joshi, Suvarna Jyothi Ganta

Department of Obstetrics and Gynecology, Chinmaya Mission Hospital, Bangalore, Karnataka, India

Received: 22 November 2019
Revised: 22 December 2019
Accepted: 31 December 2019

*Correspondence:
Dr. Saraswathi H. L.,
E-mail: dr.saras24@gmail.com

ABSTRACT
Intrahepatic cholestasis of pregnancy (ICP) is an important complication of pregnancy requiring increased surveillance by the obstetricians due to its increased foetal morbidity and mortality in the form of preterm birth, foetal distress, RDS including sudden IUD and stillbirth. The incidence of ICP is increasing due to IVF and routine administration of progesterone in early pregnancy. ICP usually presents in late second and third trimester. Here authors are presenting a case of early onset ICP (14 weeks) which developed in an IVF conception.

Keywords: Intra hepatic cholestasis of pregnancy, In vitro fertilisation, Progesterone

INTRODUCTION
Intrahepatic cholestasis of pregnancy (ICP) is a reversible form of cholestasis in late pregnancy, persisting until delivery. Obstructive cholestasis is diagnosed when otherwise unexplained pruritus occurs in pregnancy and abnormal liver function tests (LFTs) and/or raised bile acids occur in the pregnant woman and both resolve after delivery. Pruritus that involves the palms and soles of the feet is particularly suggestive. Initially, bile acids were first thought to be the direct cause of pruritus, but it is now known that the itch does not typically correlate with bile acids levels and other pruritic agents have been identified, including lysophosphatidic acid and sulphated progesterone metabolites, liver enzymes are raised by about 2-3 fold. As pruritis is very common in pregnancies occurring in 50% of normal pregnancies, pruritis with liver function abnormalities clinches the diagnosis. Pruritis may precede the onset of abnormal LFT’s by 2-3 weeks. ICP should be differentiated from other causes of jaundice in pregnancy like viral hepatitis, acute fatty liver of pregnancy, HELLP syndrome and other dermatological condition.

METHODS
Though ICP is commonly seen in late second and third trimester of pregnancy, here authors are presenting a case of early onset ICP occurring at 14 weeks of an IVF conception. A 37-year-old G2A1 married for 7 years presented at Chinmaya at mission hospital (CMH) Bangalore, with chief complaints of itching over soles and palms gradually increasing all over the body without any skin rashes. Her LFTs showed normal bilirubin, SGOT and SGPT increased 2 to 3 fold and bile acids 18.1 micromol/litr. A diagnosis of ICP was made and she was put on Ursodeoxycholic acid 300 mg twice daily and antihistamines SOS. Progesterone’s were stopped. Her UDCA was increased to 300 mg three times daily to which she responded well. She also developed GDM in the third trimester which was well controlled with diet. Around 37 weeks after explaining the risks to her and taking consent, she was given steroids and elective LSCS was done. In healthy male baby of 3.5 kgs delivered.
Post-operative period was uneventful and her LFTs after 1 week were within normal limits.

**DISCUSSION**

The etiopathology of ICP is multi factorial including genetic, hormonal and environmental factors. Genetic factors can explain familiar cases and the high incidence seen in some ethnic groups. Genetic defects occur in genes involved in bile canalicular transporting system leading to cholestasis. ABCB4 gene encoding the multi-drug resistance 3 protein (MDR3) which is a canalicular phospholipid translocator is primarily involved in subtype of progressive, familial intrahepatic cholestasis.5

Oestrogen and progesterone hormones play an important role in the causation of ICP; oestrogen is known to cause cholestasis.6 ICP is common during 3rd trimester and in multiple pregnancies associated with higher levels of hormones. ICP is known to occur much earlier in cases conceived by IVF where high oestrogen levels can be present.7

High progesterone also plays a role in the aetiology of ICP and its much earlier occurrence. 34 out of 50 women in a French prospective series conducted by BACQ Y et al observed 68% of ICP cases who were treated with oral micronized natural progesterone for risk of premature delivery.8

The levels of progesterone metabolites especially the 3β sulphated progesterone metabolite epiallopregnanalone sulphate is raise more than normal in the serum of ICP pregnancies.5 The interaction between this metabolite of progesterone and the Farnesoid X receptor (FXR) results in the aberrant expression of bile acid homeostasis.9

Progesterone’s are administered routinely in cases conceived by IVF and in cases of recurrent unexplained miscarriages which may increase the incidence of ICP.10

There is not only a higher risk of ICP among HCV-infected pregnant women but also an increased risk of later HCV infection among ICP patients. Asymptomatic hepatitis C is associated with increased risk of ICP.11

The risk of foetal death appears to increase not only with high bile acid levels but even within the physiological range after 37 weeks of gestation. Antepartum testing to identify foetuses at risk of IUD is unproven.12 Several studies reported intraterine foetal death occurring within a few days of a reactive NST. NST may be used on alternate days to detect the rare foetal heart tracing suggesting foetal compromise and the need for early delivery. The pathology of sudden foetal death is the entry of bile acids into the cardiac muscle and cause toxicity resulting in bradycardia, arrhythmias and sudden death.13 The risk of foetal complication is statistically increased at bile acids levels ≥ 40 micromol/litr.14

ICP affected pregnant women are at increased risk of developing PE, GDM, chorioamnionitis, PPh. CS.15 These women may be associated with subsequent development of hepatobiliary cancer, DM, thyroid disease, Cohn’s disease and other immune mediated disorders.16

UDCA has emerged as the most promising first line treatment for ICP. It increases bile flow and is used relieve pruritus and improve liver biochemical tests, lowers bile acids and liver enzyme levels and reduces neonatal complications.

Induction of delivery is usually done after 36-37 completed weeks. Delivery before 36 weeks maybe indicated in cases with severe unremitting pruritis where pharmacotherapy has failed, where bile acids levels are more than 100 micromol/litr.17

Postpartum LFTs should be checked 6-8 weeks after delivery there has been a high incidence of gallstones in females with history of IHCP. IHCP recurs during subsequent pregnancies in 40-60% cases with varying severity of recurrent episodes.19 Overall maternal prognosis is good and symptoms resolve rapidly within 48 hours of delivery. Long term follow up of the woman with history of ICP is recommended.

**CONCLUSION**

Progesterone’s be avoided or given in lower doses in pregnant women with a previous history of ICP and immediately withdrawn when cholestasis occurs during pregnancy. Patients with a history of cholestasis, either in pregnancy or with oral contraceptives should be monitored carefully during IVF and should be mildly stimulated. Every woman with ICP should be screened for hepatitis C.

**Funding:** No funding sources
**Conflict of interest:** None declared
**Ethical approval:** Not required

**REFERENCES**

1. Lammert F, Marschall H, Glantz A, Siegfried. Maternal intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management. 2000;33(6):1012-1.
2. Kremer AE, Martens JJ, Kulik W, Rüeff F, Kuiper EM, van Buuren HR, et al. Lyosphosphatidic acid is a potential mediator of cholestatic pruritus, Gastroenterol. 2010;139(3):1008-18.
3. Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy. World J Gastroenterol. 2009;15(17):2049-66.
4. Glantz A, Marschall HU, Mattsson LÅ. Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates. Hepatol. 2004;40(2):467-74.
5. Müllenbach R, Linton KJ, Wiltshire S, Weerasekera N, Chambers J, Elias E, Higgins CF, Johnston DG, McCarthy ML, Williamson C. ABCB4 gene sequence variation in women with intrahepatic cholestasis of pregnancy. J Med Genetics. 2003;40(5):e70.

6. Pařízek A, Dušková M, Vítek L, Šrámková M, Hill M, Adamcová K, et al. The role of steroid hormones in the development of intrahepatic cholestasis of pregnancy. Physiol Res. 2015;64.

7. Maiskar V, Surve S. Early onset intrahepatic cholestasis of pregnancy: is progesterone supplementation to be blamed for?. J Obstet Gynecol India. 2019;69:192-3.

8. Bacq Y, Sapey T, Bréchot MC, Pierre F, Fignon A, Dubois F. Intrahepatic cholestasis of pregnancy: a French prospective study. Hepatol. 1997;26(2):358-64.

9. Abu-Hayyeh S, Papacleovoulou G, Lövgren-Sandblom A, Tahir M, Oduwole O, Jamaludin NA, et al. Intrahepatic cholestasis of pregnancy levels of sulfated progesterone metabolites inhibit farnesoid X receptor resulting in a cholestatic phenotype. Hepatol. 2013;57(2):716-26.

10. Bolukbas FF, Bolukbas C, Balaban HY, Aygun C, Ignak S, Ergul E, et al. Intrahepatic cholestasis of pregnancy: spontaneous vs in vitro fertilization. Euroasian J Hepato-gastroenterol. 2017;7(2):126.

11. Wijarnpreecha K, Thongprayoon C, Sanguankeo A, Upala S, Ungprasert P. Cheungpasitporn hepatitis C infection and intrahepatic cholestasis of pregnancy: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41(1):39-45.

12. Bull L, Vargas J. Serum bile acids in intrahepatic cholestasis of pregnancy: not just a diagnostic test. Hepatol. 2014;59(4):1220-2.

13. Šimják P, Pařízek A, Vítek L, Černý A, Adamcová K, Koucký M, et al. Fetal complications due to intrahepatic cholestasis of pregnancy. J Perinatal Med. 2015;43(2):133-9.

14. Demir BC, Güneş ES, Atalay MA. Intrahepatic cholestasis of pregnancy: relationship between bile acid levels and maternal and fetal complications. Turkish J Obstet Gynecol. 2014;11(3):148.

15. Pulic A, Kim E, Esakoff T, Lacoursiere D, Shaffer B, Caughey A. Maternal pregnancy complications associated with intrahepatic cholestasis of pregnancy in a population-based cohort. Am J Obstet Gynecol. 2015;212(1).

16. Shemer EA, Stephansson O, Thuresson M, Thorsell M, Ludvigsson JF, Marschall HU. Intrahepatic cholestasis of pregnancy and cancer, immune-mediated and cardiovascular diseases: A population-based cohort study. J Hepatol. 2015;63(2):456-61.

17. Palmer KR, Xiaohua L, Mol BW. Management of intrahepatic cholestasis in pregnancy. The Lancet. 2019;393(10174):853-4.

18. Pathak B, Sheibani L, Lee RH. Cholestasis of pregnancy. Obstet Gynecol Clin North Am. 2010;37:269-82.